Abstract
BackgroundEfficacy of anti-PD-1 therapy is attributed to the presence of infiltrating antigen-specific CD8+ T-cells. Despite the success of anti-PD-1 therapy, many patients with SCCHN present with immune desert or immune...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have